.Attributes Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of people along with HER2+ state-of-the-art breast cancer cells and active or even secure mind metastases revealed regular intracranial task as well as wide spread efficiency of T-DXd.